Financials data is unavailable for this security.
View more
Year on year Protagonist Therapeutics Inc grew revenues 125.73% from 26.58m to 60.00m while net income improved from a loss of 127.39m to a smaller loss of 78.96m.
Gross margin | -- |
---|---|
Net profit margin | 53.26% |
Operating margin | 47.71% |
Return on assets | 36.35% |
---|---|
Return on equity | 40.69% |
Return on investment | 39.20% |
More ▼
Cash flow in USDView more
In 2023, Protagonist Therapeutics Inc increased its cash reserves by 48.41%, or 60.98m. Cash Flow from Financing totalled 170.48m or 284.13% of revenues. In addition the company used 70.24m for operations while cash used for investing totalled 39.26m.
Cash flow per share | 2.80 |
---|---|
Price/Cash flow per share | 15.83 |
Book value per share | 9.21 |
---|---|
Tangible book value per share | 9.21 |
More ▼
Balance sheet in USDView more
Current ratio | 13.73 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼